<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher P Denton, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John S Axford, DSc, MD, FRCP, FRCPCH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The etiology and pathogenesis of the scleroderma disorders are poorly understood. As a result, treatment of these conditions is difficult, incomplete, and not curative. (See
         <a class="medical medical_review" href="/z/d/html/7557.html" rel="external">
          "Risk factors for and possible causes of systemic sclerosis (scleroderma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7554.html" rel="external">
          "Pathogenesis of systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p>
         Patients with diffuse as opposed to limited cutaneous involvement are the most likely to have early and sometimes severe internal organ involvement. These patients are classified as having diffuse cutaneous systemic sclerosis (dcSSc). This is the subset of patients for whom systemic approaches to treatment are most often used.
        </p>
        <p>
         This topic reviews the systemic approaches to the treatment of systemic sclerosis (SSc, scleroderma). An overview of the treatment of scleroderma disorders and a discussion of the clinical manifestations and diagnosis of SSc are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">
          "Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DIFFICULTIES WITH CLINICAL TRIALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical trials that evaluate the effectiveness of therapies for systemic sclerosis (SSc) are hampered because of the following problems [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The disease is rare with heterogeneous clinical manifestations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is variable progression within each subset
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Organ-based problems require specific therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insensitive outcome measures do not necessarily measure slow increments of change
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessing global impact in a multicompartment disease is challenging
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical diversity and variable natural history make prediction of outcome difficult in placebo-treated patients in randomized trials
        </p>
        <p>
        </p>
        <p>
         Older trials were often based in a single center, had inadequate numbers of enrolled patients, were not suitably controlled (few contained a placebo arm), and discounted heterogeneity, subsets, and staging. Guidelines from the American College of Rheumatology (ACR) committee on design and outcome in clinical trials for disease-modifying drugs address these problems [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          IMMUNOMODULATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         An activated immune system may be an important stimulus to both fibrotic and vascular lesions in systemic sclerosis (SSc). Its maximum damaging effect may be in the early stages of the disease. Through the production of cytokines and growth factors, for example, initial immune activation could create autocrine loops, which require no further stimulus to perpetuate the fibrotic and vascular lesions  (
         <a class="graphic graphic_figure graphicRef67862" href="/z/d/graphic/67862.html" rel="external">
          figure 1
         </a>
         ). These loops could account for the relatively poor response to immune suppression seen in established SSc [
         <a href="#rid4">
          4
         </a>
         ]. Both
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         [
         <a href="#rid5">
          5
         </a>
         ] and
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (also known as 5-fluorouracil) [
         <a href="#rid6">
          6
         </a>
         ], for example, have failed to slow or reverse skin or internal organ involvement in placebo-controlled trials; in addition, attempts to target the immune system by lymphoplasmapheresis and total lymphoid irradiation have also been without benefit. The latter may even have accelerated worsening of gastrointestinal and pulmonary involvement [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         A number of immunotherapies are being used in SSc with varying degrees of efficacy. There are no sufficiently defined immunologic targets in SSc against which to design specific compounds, although some emerging possibilities are being developed.
        </p>
        <p>
         The role of a few of these immunosuppressive agents is discussed in more detail below. We generally discourage the use of glucocorticoids, except in low doses, because they may precipitate renal failure. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3300316741">
         <span class="h2">
          Mycophenolate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several observational studies have reported promising results with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) for skin and pulmonary fibrosis [
         <a href="#rid8">
          8-13
         </a>
         ]. One of the largest observational studies, including 326 patients from a number of European centers, that was designed to further explore treatment of diffuse cutaneous systemic sclerosis (dcSSc) with immunosuppressive agents found that MMF was well tolerated and associated with improvement in skin disease over 12 months [
         <a href="#rid13">
          13
         </a>
         ]. There was no evidence of superiority compared with other immunosuppressive agents (
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) that were also used in the cohort.
        </p>
        <p>
         Results of the SLS-II clinical trial that compared oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         over 12 months with MMF given over 24 months are supportive of the benefit for lung fibrosis and also suggest benefit for skin in both treatment arms, although the study did not include a placebo-treated arm and so should be interpreted with caution [
         <a href="#rid14">
          14,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Choice of initial agent'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in SSc remains uncertain. Its efficacy as a single agent is unknown. On the other hand, cyclophosphamide in combination with glucocorticoids or plasma exchange is possibly efficacious in some patients [
         <a href="#rid16">
          16,17
         </a>
         ], but controlled studies have not been performed. We primarily use cyclophosphamide in combination with glucocorticoids for patients with fibrosing alveolitis who do not yet have advanced fibrosis. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Initiating therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term, high-dose glucocorticoids are potentially toxic and have been implicated in precipitating renal crisis [
         <a href="#rid18">
          18
         </a>
         ]. Any use of such glucocorticoids may increase the risk of this complication [
         <a href="#rid19">
          19
         </a>
         ]. Glucocorticoids should therefore be restricted to patients with myositis, active fibrosing alveolitis, symptomatic serositis, the early edematous phase of the skin disease, refractory arthritis, and tenosynovitis (see
         <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">
          "Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults"
         </a>
         ). The lowest possible effective dose should be used in these settings, preferably below 10 mg/day of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         .
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Cyclosporine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         suppresses cell-mediated immunity and also reduces collagen synthesis. However, the therapeutic potential of cyclosporine in SSc is limited by nephrotoxicity. In one report, for example, three of eight patients developed hypertension and acute renal failure after the onset of cyclosporine therapy; the causal relation to the drug could not be determined [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         There is preliminary information that suggests that
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         may be helpful in controlling some aspects of SSc [
         <a href="#rid21">
          21,22
         </a>
         ]. One study evaluated 10 patients without hypertension or renal disease [
         <a href="#rid22">
          22
         </a>
         ]. Skin thickening diminished significantly, but there was no change in cardiac or pulmonary disease. Nephrotoxicity was seen at doses above 3 to 4 mg/kg per day. We do
         <strong>
          not
         </strong>
         use cyclosporine because its toxicity appears to outweigh any potential clinical benefit.
        </p>
        <p>
         Controlled observations are clearly needed. It is also possible that other cyclophilins, such as rapamycin, will provide more targeted immunosuppression, improved efficacy, and less toxicity [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Other immunosuppressive agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other immunosuppressive agents have been used in SSc with varying degrees of efficacy and have been evaluated in trials of varying scientific rigor. By comparison, MTX has been evaluated in randomized, double-blind trials with inconclusive results [
         <a href="#rid24">
          24-27
         </a>
         ]. Although these were not considered to be strongly suggestive of clinical benefit by the investigators, there is some evidence for superiority over placebo, especially with respect to modified Rodnan skin score (mRSS). The European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) recommendations for treatment of SSc have thus offered some support to the use of MTX for skin disease [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         A small study of rapamycin has been conducted, but it was not powered for efficacy analysis [
         <a href="#rid23">
          23
         </a>
         ]. This may be a strategy warranting further study.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Autologous stem cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies of autologous hematopoietic stem cell transplantation (HSCT) have demonstrated efficacy in preventing disease progression in SSc patients [
         <a href="#rid29">
          29-40
         </a>
         ]. However, the high incidence of treatment-related mortality (TRM) has limited its use in the management of SSc, and patients should be made to understand the potential risks of this procedure. The major complications associated with HSCT for SSc include treatment-related deaths, malignancies, and infections. The particular challenge is that cardiopulmonary or renal involvement from SSc may make the chemotherapy and fluid load associated with mobilization and conditioning extremely hazardous, and so early TRM is a particular risk. Careful assessment pre-HSCT is essential to minimize TRM.
        </p>
        <p>
         Based upon emerging trial data and our own experience, HSCT may be most beneficial in selected patients with early, severe dcSSc. These patients may have moderate (but not severe) internal organ involvement and progressive disease despite an initial trial of immunosuppression. However, such patients should be referred for further evaluation to specialized centers with expertise performing HSCT for SSc. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Hematopoietic stem cell transplantation'
         </a>
         .)
        </p>
        <p>
         In a randomized trial (Scleroderma:
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         or Transplantation [SCOT]) including 75 patients with severe SSc of five years' or less duration and pulmonary or renal involvement, patients were assigned to receive either myeloablative autologous HSCT or 12 monthly cyclophosphamide infusions [
         <a href="#rid40">
          40
         </a>
         ]. The primary endpoint was a global rank composite score that compared each individual patient with all other patients on the basis of a hierarchy of disease features assessed at 54 months, with rankings from highest to lowest for death, event-free survival, forced vital capacity, scores on the Health Assessment Questionnaire Disability Index, and Rodnan skin score. In the intention-to-treat analysis, global rank composite scores favored transplantation over cyclophosphamide (67 percent of 1404 pairwise comparisons favored transplantation and 33 percent favored cyclophosphamide). Secondary per-protocol analyses of the global rank composite scores and traditional endpoints (ie, overall survival, event-free survival, modified Rodnan skin score, and disease-modifying antirheumatic drug [DMARD] use) were consistent with the primary outcome, favoring transplantation. The transplant-related mortality was 3 percent at 54 months and 6 percent at 72 months, which is less than that reported in previous studies. However, this difference in mortality from previous trials may reflect differences in baseline patient factors, such as the exclusion of patients with heart involvement or pulmonary arterial hypertension.
        </p>
        <p>
         The Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial, which used a nonmyeloablative transplantation, is the largest multicenter study of the safety and efficacy of treatment with autologous HSCT compared with conventional
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         therapy in patients with early dcSSc [
         <a href="#rid41">
          41
         </a>
         ]. A total of 156 dcSSc patients were randomly assigned to receive either HSCT (n = 79) or 12 monthly pulses of intravenous cyclophosphamide (n = 77). The primary endpoint was event-free survival, which was defined as the time until death due to any cause or the development of persistent major organ failure (eg, heart, lung, or kidney). Secondary endpoints included TRM, toxicity, changes in skin thickening, organ function, and quality of life. HSCT resulted in worse early, but better long-term, event-free and overall survival:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During the first year, the number of events was higher in the HSCT group (13 versus 8 events). Most of these events in the HSCT group occurred during the first three to six months after transplant, and most were treatment-related (8 of 13). However, between the first and fourth years of follow-up, an additional two events occurred in the HSCT group compared with an additional 12 events in the
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since the increased number of events in the HSCT group occurred within the first six months, the event-free survival actually favors HSCT at two years (hazard ratio 0.35, 95% CI 0.16-0.74) and at four years (hazard ratio 0.34, 95% CI 0.16-0.74).
        </p>
        <p>
        </p>
        <p>
         Consistent with previous studies [
         <a href="#rid29">
          29,31,34,35
         </a>
         ], the ASTIS trial also found that HSCT was associated with significant improvements in lung function, skin softness, functional ability, and quality of life. However, HSCT produced a higher incidence of viral infections and a significant decrease in creatinine clearance. Finally, seven of the eight patients who died from HSCT-related causes were current or former smokers.
        </p>
        <p>
         Patient selection is thought to be a critical factor in determining successful outcomes of HSCT. Specifically, TRM and lack of improvement of diffusion capacity may partly reflect the selection of patients with more severe cardiorespiratory disease that may not always be apparent on pre-HSCT evaluation. A retrospective analysis of 90 patients with SSc who underwent HSCT on a compassionate basis suggested that cardiac screening guidelines for HSCT for SSc should be more extensive, including right heart catheterization, a fluid challenge test, and cardiac magnetic resonance imaging (MRI) in addition to echocardiography [
         <a href="#rid35">
          35
         </a>
         ]. Improvement in diffusion capacity was observed in patients with normal baseline cardiac function and electrocardiographic findings. In addition, the results of the ASTIS trial described above also suggest that the smoking status of patients may impact outcomes of HSCT [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         These findings support the need for early referral of patients for HSCT, before cardiac dysfunction occurs, along with screening guidelines for patients with SSc under evaluation for HSCT [
         <a href="#rid35">
          35,42,43
         </a>
         ]. SSc patients should undergo standard screening for internal organ involvement as well as cardiopulmonary evaluations combining pulmonary function tests, echocardiography, cardiac MRI, and invasive hemodynamic studies if clinically indicated. In general, patients are selected based upon criteria used for enrollment in clinical trials that demonstrate a therapeutic benefit of HSCT [
         <a href="#rid34">
          34,41
         </a>
         ]. As noted earlier, patients considered for HSCT should be referred to specialized centers with expertise in the procedure for further evaluation and treatment. Our approach to the pre-transplant cardiopulmonary evaluation for SSc patients is consistent with guidelines published by the European Society for Blood and Marrow Transplantation [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Appropriate case selection remains challenging because those patients with more severe organ-based disease are generally excluded from trial protocols despite poor outcome with standard immunosuppression. Future trial protocols will assess benefit of HSCT as first-line therapy [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          ANTIFIBROTIC DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of established fibrosis is a very difficult therapeutic problem, since there is no safe and effective method of removing excess insoluble cross-linked collagen fibers without damaging the structural framework of the body and individual organs. Fibrotic lesions may occur with frightening speed in patients with systemic sclerosis (SSc). This fact, alone, would justify starting an antifibrotic drug as soon as possible in patients with diffuse disease and possibly administering such a drug concurrently with an immunosuppressive agent.
        </p>
        <p>
         The major problems with the available antifibrotic drugs are that they are slow to act and are often not powerful enough to prevent rampant fibrosis. As a result, escalation of the drug dose in the proper setting should be as rapid as possible.
        </p>
        <p>
         Antifibrotic drugs are
         <strong>
          not
         </strong>
         necessary for cutaneous manifestations in patients with limited cutaneous SSc (lcSSc), but a careful watch should be kept for significant visceral fibrosis among such patients. The use of the ever-improving "antibody-based" risk stratification for internal organ involvement may permit the early identification and appropriate treatment of lung fibrosis  (
         <a class="graphic graphic_table graphicRef59732" href="/z/d/graphic/59732.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          D-penicillamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          D-penicillamine
         </a>
         is a drug capable of affecting both collagen biosynthesis and the immune system. One possible mechanism is that autoantibodies in SSc are formed against autoantigens that have been fragmented via reactive oxygen species and specific metals, such as copper or iron [
         <a href="#rid45">
          45
         </a>
         ]. Penicillamine, a chelator of metals, may therefore minimize the formation of these autoantigens. (See
         <a class="medical medical_review" href="/z/d/html/7554.html" rel="external">
          "Pathogenesis of systemic sclerosis (scleroderma)", section on 'Autoantibodies'
         </a>
         .)
        </p>
        <p>
         The precise role of
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         in the treatment of SSc has not been determined. Estimates of the efficacy of penicillamine and the effect upon survival can be found in uncontrolled studies published by several groups with extensive experience with this drug. The possible benefit of penicillamine can be illustrated by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective analysis from Pittsburgh compared 73 patients with SSc who had received
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         with 45 patients who had not [
         <a href="#rid46">
          46
         </a>
         ]. The mean daily dose of penicillamine varied from 500 to 1500 mg, and therapy was given for a mean period of 24 months. The mean follow-up was at least three years. Patients treated with penicillamine showed an improved cumulative five-year survival (80 percent) and a lower rate of new visceral involvement compared with patients not exposed to penicillamine. Except for skin softening, other intergroup differences did not reach statistical significance [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another group reported their 15-year, uncontrolled experience with
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         in SSc [
         <a href="#rid47">
          47
         </a>
         ]. This study consisted of 69 selected patients with diffuse disease of less than 18 months' duration in whom a 30 percent increase in skin involvement had occurred in the preceding six months. Treatment with penicillamine (750 mg/day) for at least six months was associated with a 75 percent improvement in skin sclerosis (from 65 to 16 percent of total body surface) and with an 80 percent five-year cumulative survival rate. Renal disease was uncommon, and pulmonary disease was not progressive in patients treated for more than six months.
        </p>
        <p>
        </p>
        <p>
         These and other studies have noted that skin sclerosis worsened during the first four to six months despite therapy. This observation emphasizes the necessity for the development of a rapidly acting antifibrotic agent.
        </p>
        <p>
         To assess the effects of high-dose
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         on disease activity, 134 patients with early diffuse cutaneous SSc (dcSSc) were enrolled in a multicenter double-blind randomized study comparing high-dose (750 to 1000 mg/day) with low-dose (125 mg every other day) therapy [
         <a href="#rid48">
          48
         </a>
         ]. Sixty-eight patients completed 24 months of therapy. No significant differences were observed between the two treatment groups with respect to the skin thickness scores and the incidence of renal crisis and mortality. However, 16 of the 20 adverse event-related withdrawals occurred in the high-dose treatment group. Although this study could not answer the question of whether low-dose penicillamine is effective, there appeared to be no advantage in using high-dose penicillamine. Based upon the results of this key trial, we do not initiate penicillamine therapy for SSc. However patients who are stable on therapy may be continued, with dose reduction toward the low dose used in the controlled trial (125 mg every other day).
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Interferons
         </span>
         <span class="headingEndMark">
          —
         </span>
         The interferons have been reported to be beneficial in the therapy of various diseases, including SSc. In particular, an antifibrotic effect has been reported in vitro. However, subsequent data have implicated interferons in the pathogenesis of some autoimmune diseases. Interferon (IFN)-gamma is a more potent inhibitor of collagen synthesis in vitro than IFN-alpha. It has other effects, however, which may contribute to aberrant cellular activation in SSc (see
         <a class="medical medical_review" href="/z/d/html/7554.html" rel="external">
          "Pathogenesis of systemic sclerosis (scleroderma)"
         </a>
         ). As examples, in vitro IFN-gamma can lead to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrophage activation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Class II antigen expression (DR, DP, DQ) on endothelial and fibroblast cells
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased interleukin (IL) 2 receptor expression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased intracellular adhesion molecule-1 expression on endothelial cells
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin G (IgG) Fc receptor expression
        </p>
        <p>
        </p>
        <p>
         These concerns have been apparently confirmed in uncontrolled studies in which IFN-gamma was associated with considerable vascular side effects, including renal hypertensive crisis [
         <a href="#rid49">
          49
         </a>
         ]. As a result, no controlled studies are planned, and the studies that have been performed provide evidence that in some cases IFN may be a driver of pathology in SSc.
        </p>
        <p>
         IFN-alpha has received less attention than IFN-gamma. A pilot study of 14 patients with early diffuse disease of less than three years' duration found a significant measurable reduction in type I collagen synthesis by fibroblasts cultured from uninvolved skin and found stabilization or improvement in the skin test in 10 of the patients [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         However, a multicenter double-blind study of 35 patients found that IFN-alpha provides no increased benefit compared with placebo and may be deleterious [
         <a href="#rid51">
          51
         </a>
         ]. In this report, patients with early SSc were randomized to IFN-alpha (13.5 million units per week given subcutaneously for 12 months) or placebo. Compared with the placebo group, intent-to-treat analysis found that the group treated with IFN-alpha had more substantial skin involvement (as assessed by the skin score) and had a significantly greater deterioration in lung function (as assessed by the forced vital capacity [p = 0.01] or by the diffusing capacity for carbon monoxide [p = 0.002]).
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Iloprost
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to vasodilating effects,
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         may also have antifibrotic properties. Among six patients with dcSSc, five days of iloprost infusion decreased the dermal interstitial fluid concentration of the profibrotic cytokine, connective tissue growth factor [
         <a href="#rid52">
          52
         </a>
         ]. However, objective evidence of a clinically important antifibrotic effect has not been established. Iloprost is not available in the United States, but both oral and intravenous preparations are available in some other countries. It has not been determined whether its effects are shared with other prostacyclin analogues, such as
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         .
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Relaxin
         </span>
         <span class="headingEndMark">
          —
         </span>
         A natural antifibrotic protein, relaxin, is produced during pregnancy by the uterus and the corpus luteum. It promotes the degradation of collagen and antagonizes the production of new collagen by fibroblasts. Despite encouraging trends in a small controlled trial, a subsequent larger multicenter trial did not find any benefit from relaxin, and withdrawal of relaxin was associated with serious renal adverse events [
         <a href="#rid53">
          53,54
         </a>
         ]. Further commercial development of this agent for treatment of SSc is not being considered.
        </p>
        <p class="headingAnchor" id="H214322511">
         <span class="h2">
          Anti-TGF-beta
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first trial of anti-transforming growth factor beta (TGF-beta) in SSc was negative. Metelimumab, a monospecific antibody targeting TGF-beta1 was found to be of low affinity, and the trial did not demonstrate benefit for skin fibrosis. A more potent anti-TGF-beta-specific antibody targeting all the TGF-beta isoforms, fresolimumab, was tested in an open-label study with clinical improvement and consistent data from molecular markers in skin biopsies [
         <a href="#rid55">
          55
         </a>
         ]. This provides a platform for possible future treatment strategies in SSc that target TGF-beta ligands. The universal importance of TGF-beta in fibrosis and availability of therapeutics targeting this ligand and related signaling pathways makes this a compelling strategy. However, until this is shown to be both safe and effective, it remains very much in the research arena.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Anticytokine therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Better understanding of likely key mediators in pathogenesis has raised the possibility of targeted therapy. As discussed above, there is already evidence that conventional treatments such as parenteral prostacyclin suppress key profibrotic factors, such as connective tissue growth factor (CTGF). Endothelin antagonism may also attenuate TGF-beta signaling [
         <a href="#rid56">
          56
         </a>
         ]. Anti-tumor necrosis factor (TNF)-alpha agents, while theoretically attractive, have not proven to be beneficial in clinical trials [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
         When recombinant anti-TGF-beta1 (investigational agent CAT-192) was assessed in a small pilot study, no adverse effects were noted, but neither was there any suggestion of efficacy [
         <a href="#rid59">
          59
         </a>
         ]. This result suggests that blockade of more than one isoform of TGF-beta may be necessary.
        </p>
        <p>
         The use of combinations of anticytokine therapies (eg, the use of agents directed against both TGF beta and CTGF) is being explored [
         <a href="#rid60">
          60
         </a>
         ]. In addition, it is possible that the vasoconstrictor peptide endothelin may have a specific role in fibrosis, and potentially broader use outside the complication of pulmonary arterial hypertension is being explored.
        </p>
        <p class="headingAnchor" id="H879744233">
         <span class="h2">
          Tocilizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although IL-6 was originally characterized as a proinflammatory mediator with potent effects on the adaptive immune system, it is emerging as a potent mediator that is produced by a large number of cell types in response to damage or activation.
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          Tocilizumab
         </a>
         , a humanized anti-human IL-6 receptor antibody, has been shown to have potent antifibrotic activity in vitro, and this may result from its ability to signal through many cell types via the glycoprotein (gp) 130 trans-signaling system. Data from clinical trials have suggested a potential antifibrotic effect of blocking IL-6 signaling using tocilizumab [
         <a href="#rid61">
          61-63
         </a>
         ]. In one trial, there was trend of benefit for skin fibrosis and lung function [
         <a href="#rid63">
          63
         </a>
         ]. The focuSSced trial replicated these results, again only showing a trend of benefit overall for skin in a population with milder disease, but with a statistically significant reduction in the progression of skin fibrosis and robust impact on lung function and on HRCT-confirmed lung fibrosis (NCT02453256). This impact appears to be greatest in those cases with early-stage active skin disease and markers of increased acute phase response that are associated with elevated levels of serum IL-6. One small case series indicates that discontinuation of tocilizumab may be associated with disease recrudescence [
         <a href="#rid64">
          64
         </a>
         ]. On the basis of its impact on lung function and HRCT severity in the phase 3 focuSSced trial, tocilizumab is now approved by the US Food and Drug Administration (FDA) as treatment to slow progression of lung fibrosis in SSc [
         <a href="#rid65">
          65,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3017027586">
         <span class="h2">
          Nintedanib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         , a tyrosine kinase inhibitor in routine use for treatment of idiopathic lung fibrosis (IPF), is now approved for use in patients with SSc-associated interstitial lung disease (ILD) [
         <a href="#rid67">
          67
         </a>
         ] and progressive ILD in connective tissue disease [
         <a href="#rid68">
          68
         </a>
         ]. The role of this drug in the treatment of ILD for patients with SSc is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Nintedanib'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H222116021">
         <span class="h2">
          Pirfenidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          Pirfenidone
         </a>
         is also in routine use as an antifibrotic agent in IPF, although the mechanism of action is less clear than for
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         . It has not yet been formally tested in a large trial of SSc-associated ILD, but a small open-label safety study demonstrated that it was well tolerated in SSc [
         <a href="#rid69">
          69
         </a>
         ]. An ongoing trial aims to address the potential value of adding pirfenidone on top of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) in a large cohort of SSc-ILD cases (NCT03221257).
        </p>
        <p class="headingAnchor" id="H425008985">
         <span class="h2">
          Immunosuppression as an indirect antifibrotic approach: MMF, cyclophosphamide, HSCT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The distinction between antifibrotic and immunomodulatory treatment for SSc is increasingly challenged by data emerging from clinical trials and observational cohorts that demonstrate improvement or slowing in progression of fibrosis in skin or lung after treatment strategies that are primarily immunosuppressive or antiinflammatory. This is also supported by data from preclinical and translational studies. Thus,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and MMF have both been associated with trends of improvement in skin and lung based on analysis of trial cohorts [
         <a href="#rid13">
          13,14,70
         </a>
         ]. Most persuasive are the data from trials of autologous hematopoietic stem cell transplantation (HSCT), where there is clear evidence of reversal of skin fibrosis assessed by modified Rodnan skin scores (mRSS) and lung fibrosis assessed by lung function testing and quantitative high-resolution computed tomography (HRCT) analysis (see
         <a class="local">
          'Autologous stem cell transplantation'
         </a>
         above). Similarly, results from a trial of
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         , a humanized anti-human IL-6 receptor antibody, have suggested potential benefit on lung fibrosis. (See
         <a class="local">
          'Tocilizumab'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          INVESTIGATIONAL APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is an urgent need to improve our repertoire of antifibrotic agents and develop novel therapeutic approaches to systemic sclerosis (SSc). A growing understanding of the cellular and molecular events that lead to fibrosis and improvements in technology provide a favorable basis for the development of effective agents. Potentially promising approaches for the treatment of SSc include the following:
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Imatinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         mesylate, a protein tyrosine kinase inhibitor, is highly effective for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors, and limited data suggest possible benefit in patients with SSc. The selective inhibition of tyrosine kinase interferes with the signaling of both platelet-derived growth factor (PDGF) and transforming growth factor (TGF)-beta, two pivotal mediators of the fibrotic process in SSc [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         An open-label prospective study of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (400 mg/day) in 30 patients with diffuse cutaneous SSc (dcSSc), but without controls, showed improvement in modified Rodnan skin scores (mRSS) and in forced vital capacity compared with baseline after 12 months [
         <a href="#rid72">
          72
         </a>
         ]. Mild to moderate adverse effects were common, including edema requiring treatment with diuretics. The most common causes of dose adjustment or interruption in therapy were musculoskeletal complaints, fluid-related issues, intercurrent illnesses, gastrointestinal complaints, and constitutional symptoms (37, 27, 23, 23, and 20 percent, respectively). Randomized trials will be required to distinguish possible benefit from imatinib from natural history of disease or from effects of other interventions.
        </p>
        <p>
         The theoretical basis supporting use of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         includes findings of an in vitro study of fibroblasts from SSc patients, in which cells isolated and cultured from lesional skin were stimulated with TGF-beta and PDGF and were then exposed to imatinib [
         <a href="#rid73">
          73
         </a>
         ]. This led to the inhibition of extracellular matrix protein production in a dose-dependent manner. In a separate study, imatinib blocked, in vitro, the Smad1/CCN2 pathway, which is also implicated in the development of fibrosis [
         <a href="#rid74">
          74
         </a>
         ]. Furthermore, four case reports suggest that imatinib may reduce fibrosis in several clinical settings [
         <a href="#rid75">
          75-78
         </a>
         ].
        </p>
        <p>
         Other protein tyrosine kinase inhibitors are also being studied for possible antifibrotic effects. These include
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         [
         <a href="#rid79">
          79
         </a>
         ]. In addition, the two licensed drugs for idiopathic lung fibrosis,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         and
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         , have been suggested as potentially useful agents for lung or skin fibrosis in SSc, but formal clinical trial data are needed to assess this [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Investigational approaches'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a growing evidence base supporting use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         as a B-cell-depleting agent in SSc. Data from case series and small clinical trials have been generally positive, and a retrospective cohort analysis from the large European Scleroderma Trials and Research group (EUSTAR) cohort also suggested benefit compared with standard immunosuppression. However, the precise mechanism of benefit is less clear, and it may be that a subset of patients is driving the overall treatment response. B-cell infiltration has been demonstrated within skin and lung biopsies of SSc patients, and limited data have suggested improvement in skin and lung disease with B-cell depletion [
         <a href="#rid81">
          81-91
         </a>
         ]. One of the larger studies to assess the effects of rituximab on skin and lung fibrosis included 63 SSc patients treated with rituximab compared with 25 matched controls [
         <a href="#rid90">
          90
         </a>
         ]. After a follow-up period of approximately seven months, patients treated with a single course of rituximab demonstrated a significant improvement in the mRss. Among SSc patients with interstitial lung disease (ILD), rituximab also prevented a further decline in forced vital capacity compared with matched controls. There were no serious adverse events among rituximab-treated patients. An open-label randomized trial including 60 patients assigned to receive either rituximab or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         found that patients receiving rituximab demonstrated greater improvements in the percent-predicted forced vital capacity as well as the mRSS compared with the cyclophosphamide group [
         <a href="#rid92">
          92
         </a>
         ]. However, additional studies are needed to establish the long-term efficacy and safety of rituximab for skin and lung fibrosis in SSc before routine use can be recommended. A small trial in Japan reported benefit of rituximab compared with placebo for improving skin score in SSc and also demonstrated benefit for lung function [
         <a href="#rid93">
          93
         </a>
         ]. The drug is now approved for treatment of SSc in Japan. The role of rituximab in the treatment of patients with ILD in SSc is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Rituximab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Intravenous immunoglobulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are case series and small trials suggesting potential benefit from intravenous immunoglobulin for skin fibrosis as well as other symptoms, including gastrointestinal tract manifestations, of SSc. Clinical trials are being planned, but the mechanism of action for antifibrotic activity remains unclear. Several small, uncontrolled studies have evaluated the effect of intravenous administration of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         on dermal fibrosis, each with reported improvement [
         <a href="#rid79">
          79,94
         </a>
         ]. The largest series to evaluate the effect of IVIG on active cutaneous disease included 30 patients with refractory dcSSc, the majority of whom were on concomitant immunosuppressive therapy [
         <a href="#rid94">
          94
         </a>
         ]. A significant improvement in skin thickening was detected at 12 months compared with historical controls from negative clinical trials. In addition, a group of patients treated with IVIG demonstrated an improvement in the mRSS that was similar to a group of patients treated with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF).
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Epigenetic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epigenetic changes, which are stable phenotypic changes that persist in a heritable manner but which are not the result of changes in deoxyribonucleic acid (DNA) sequence, may play a role in the profibrotic myofibroblasts of patients with SSc. Agents that interfere with deacetylation of histone proteins may limit the ability of transformed cells to proliferate. The protein deacetylase enzyme inhibitor trichostatin A is being assessed for possible antifibrotic effects [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7554.html" rel="external">
          "Pathogenesis of systemic sclerosis (scleroderma)", section on 'Fibroblast activity and collagen synthesis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">
          "Genetics: Glossary of terms", section on 'Epigenetic change'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14601.html" rel="external">
          "Principles of epigenetics", section on 'Therapeutic uses'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Immune tolerance induction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another possible approach to the treatment of SSc is the induction of T-cell tolerance by the administration of oral bovine type I collagen. This approach was evaluated in a randomized, placebo-controlled trial in which 168 patients were assigned to 12 months of therapy with oral bovine type I collagen (160 mg daily) or placebo [
         <a href="#rid95">
          95
         </a>
         ]. The primary outcome, change in the mRSS, was not different from placebo-treated patients at 12 or 15 months of follow-up in the total population of treated patients. However, in a secondary subgroup analysis, treated patients with late-phase disease (more than 3 to 10 years) had a significant reduction in mRSS. Further studies are required.
        </p>
        <p class="headingAnchor" id="H3301475847">
         <span class="h2">
          Other agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Riociguat
         </strong>
         – A trial of
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         was performed in very early-stage cases of diffuse SSc to explore potential for prevention of worsening of skin fibrosis [
         <a href="#rid96">
          96
         </a>
         ]. Despite strong preclinical support and trend of benefit, the study was considered negative, and this approach to treatment of skin fibrosis is not being pursued for fibrosis, although benefit for vasculopathy has been observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endothelin antagonist
         </strong>
         – There is no evidence to support an antifibrotic effect of endothelin receptor antagonists such as
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          bosentan
         </a>
         , despite benefit for reduction in number of new digital ulcers in SSc and use for pulmonary arterial hypertension. The Bosentan Use in Interstitial Lung Disease (BUILD)-2 trial was a robust study that failed to demonstrate any benefit for lung fibrosis in SSc-ILD and a parallel study in idiopathic lung fibrosis (IPF; BUILD-1) was also negative [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lanifibranor
         </strong>
         – There are strong preclinical data supporting a potential antifibrotic role for the nuclear hormone receptor peroxisome proliferator-activated receptor (PPAR) gamma [
         <a href="#rid98">
          98
         </a>
         ]. This led to a completed phase 2 clinical trial exploring potential benefit of lanifibranor, a pan-PPAR agonist, for skin fibrosis in dcSSc. The data have not yet been fully reported, but the primary endpoint was not met, and there is no evidence that this approach to treating skin or other aspects of SSc is beneficial. This illustrates the challenges of extrapolating from strong preclinical results to identify potential benefit in human disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lenabasum
         </strong>
         – Lenabasum is a synthetic endocannabinoid that selectively activates the CB2 receptor that is expressed on many cell types, including fibroblasts and immune cells. Mechanistic data suggest an antifibrotic and immunomodulatory effect, which promotes resolution of injury responses and which may be helpful in a number of chronic diseases characterized by scarring in response to tissue damage, including SSc. A small phase 2 trial over 16 weeks with open-label extension supported benefit, but a large phase 3 trial was negative overall in SSc and so clinical development is not continuing [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Romilkimab
         </strong>
         – Targeting cytokines that may link immune-inflammation and fibrosis is an attractive strategy, and this has led to present evaluation of romilkimab, a bispecific antibody that binds to IL-4 and IL-13. This trial will soon report the primary data and, if positive, may provide an additional investigational approach to treatment for skin or lung fibrosis in SSc. No results from the study are yet available.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3092877969">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118282.html" rel="external">
          "Society guideline links: Systemic sclerosis (scleroderma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (SSc), while theoretically appealing, have not been shown to be more beneficial than harmful. While recognizing the limited data available to guide therapy, we recommend the following agents in certain circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The combination of glucocorticoids and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         may be used in patients with severe or progressive lung fibrosis in SSc who have yet to develop advanced fibrotic lung disease. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Initiating therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoids, preferably in doses of less than the equivalent of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         10 mg/day, may be used for myositis, symptomatic serositis, arthritis, or tenosynovitis that is refractory to use of nonsteroidal antiinflammatory drugs (NSAIDs). (See
         <a class="local">
          'Cyclophosphamide'
         </a>
         above and
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Emerging data suggest that high-intensity immunosuppression may benefit skin and function in diffuse cutaneous SSc (dcSSc), but high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         with autologous stem cell rescue may be associated with significant treatment-related mortality (TRM). Thus, case selection to target patients in whom the risk-to-benefit ratio is most favorable is critical. (See
         <a class="local">
          'Autologous stem cell transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several case reports and one phase 3 trial suggest improvement in skin and lung disease with B-cell depletion. However, additional studies are needed to establish the long-term efficacy and safety of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in SSc patients before routine use can be recommended. (See
         <a class="local">
          'Rituximab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is an urgent need to improve our repertoire of antifibrotic agents and develop novel therapeutic approaches to SSc. A growing understanding of the cellular and molecular events that lead to fibrosis and improvements in technology provide a favorable basis for the development of effective agents. (See
         <a class="local">
          'Investigational approaches'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pope JE, Bellamy N. Outcome measurement in scleroderma clinical trials. Semin Arthritis Rheum 1993; 23:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denton CP. Challenges in systemic sclerosis trial design. Semin Arthritis Rheum 2019; 49:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White B, Bauer EA, Goldsmith LA, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995; 38:351.
          </a>
         </li>
         <li class="breakAll">
          Black CM, Denton CP. Scleroderma. In: Role of Cytokines in Autoimmunity, Brennan FM, Feldmann M (Eds), 1996. p.153.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989; 32:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casas JA, Saway PA, Villarreal I, et al. 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study. Ann Rheum Dis 1990; 49:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Dell JR, Steigerwald JC, Kennaugh RC, et al. Lack of clinical benefit after treatment of systemic sclerosis with total lymphoid irradiation. J Rheumatol 1989; 16:1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) 2007; 46:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le EN, Wigley FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derk CT, Grace E, Shenin M, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009; 48:1595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrick AL, Lunt M, Whidby N, et al. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010; 37:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 2017; 76:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denton CP. Scleroderma Lung Study II-clarity or obfuscation? Lancet Respir Med 2016; 4:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentini G, Paone C, La Montagna G, et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006; 35:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akesson A, Wollheim FA, Thysell H, et al. Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis. Scand J Rheumatol 1988; 17:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46:2983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denton CP, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994; 33:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appelboom T, Itzkowitch D. Cyclosporine in successful control of rapidly progressive scleroderma. Am J Med 1987; 82:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993; 36:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su TI, Khanna D, Furst DE, et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 2009; 60:3821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007; 19:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol 2009; 36:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100:1602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Marolleau JP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002; 119:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miniati I, Guiducci S, Conforti ML, et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis 2009; 68:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burt RK, Oliveira MC, Shah SJ, et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006; 45:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Gluckman E. Autologous HSCT in systemic sclerosis: a step forward. Lancet 2011; 378:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Laar J, Farge D, Sont J, et al. High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis. Arthritis Rheum 2012; 64:4167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloth C, Maximilian Thaiss W, Preibsch H, et al. Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests. Rheumatology (Oxford) 2016; 55:1763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311:2490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snowden JA, Akil M, Kiely DG. Improving safety in autologous HSCT for systemic sclerosis. Lancet 2013; 381:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Burt RK, Oliveira MC, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant 2017; 52:1495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spierings J, Nihtyanova SI, Derrett-Smith E, et al. Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2022; 61:1948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997; 185:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steen VD, Medsger TA Jr, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982; 97:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment]. J Rheumatol 1991; 18:1496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freundlich B, Jimenez SA, Steen VD, et al. Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. Arthritis Rheum 1992; 35:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens W, Vancheeswaran R, Black CM. Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis Study Group. Br J Rheumatol 1992; 31:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice LM, Padilla CM, McLaughlin SR, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125:2795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shi-wen X, Kennedy L, Renzoni EA, et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007; 56:4189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Distler JH, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 2008; 58:2228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denton CP, Engelhart M, Tvede N, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009; 68:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denton CP, Abraham DJ. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001; 13:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denton CP, Ong VH, Xu S, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis 2018; 77:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387:2630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis 2018; 77:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isomura Y, Shirai Y, Kuwana M. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Rheumatology (Oxford) 2022; 61:4491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna D, Lin CJF, Furst DE, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med 2022; 205:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna D, Lescoat A, Roofeh D, et al. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Arthritis Rheumatol 2022; 74:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 2019; 380:2518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381:1718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanna D, Albera C, Fischer A, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol 2016; 43:1672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pannu J, Asano Y, Nakerakanti S, et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008; 58:2528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Daele PL, Dik WA, Thio HB, et al. Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 2008; 58:2549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Distler JH, Manger B, Spriewald BM, et al. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 2008; 58:2538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58:2543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 2009; 60:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Distler J, Distler O. Novel treatment approaches to fibrosis in scleroderma. Rheum Dis Clin North Am 2008; 34:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volkmann ER, Tashkin DP. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann Am Thorac Soc 2016; 13:2045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007; 56:3167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoussis D, Liossis SN, Tsamandas AC, et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010; 40:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010; 69:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoussis D, Andonopoulos AP, Liossis SN. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum 2010; 39:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30:S17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McQueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology (Oxford) 2015; 54:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014; 19:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013; 40:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 2018; 57:2106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): A double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 2021; 3:E489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poelman CL, Hummers LK, Wigley FM, et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 2015; 42:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postlethwaite AE, Wong WK, Clements P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008; 58:1810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagaraja V, Spino C, Bush E, et al. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Res Ther 2019; 21:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010; 62:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruzehaji N, Frantz C, Ponsoye M, et al. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2016; 75:2175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiera R, Kuwana M, Khanna D, et al. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 2023; 75:1608.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7549 Version 39.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8235663" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Outcome measurement in scleroderma clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31779848" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Challenges in systemic sclerosis trial design.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7880189" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7880189" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2655606" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2256740" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2573727" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lack of clinical benefit after treatment of systemic sclerosis with total lymphoid irradiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157146" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16899504" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21378404" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19846575" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19955050" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28188239" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27469583" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27469582" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Scleroderma Lung Study II-clarity or obfuscation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16467039" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3212403" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9751093" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12428241" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8162467" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3565449" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cyclosporine in successful control of rapidly progressive scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8424841" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19950289" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8624641" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11407694" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17917543" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19040308" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19147617" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249325" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12176878" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17452515" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12437652" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18308744" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Autologous stem cell transplantation improves microcirculation in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21777972" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23363664" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16777856" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Adult stem cells in the treatment of autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21777973" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Autologous HSCT in systemic sclerosis: a step forward.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27330164" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29298160" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25058083" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23363663" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Improving safety in autologous HSCT for systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28530671" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34314500" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8996243" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7137731" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1765974" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10366112" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1418004" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1393375" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10025924" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11457877" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10836913" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19333948" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26098215" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18050250" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18668576" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The controversial role of tumor necrosis factor alpha in fibrotic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18782794" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195236" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11698729" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29853453" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27156934" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29066464" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35258561" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34851799" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34313399" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31112379" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31566307" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27370878" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17717203" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15207816" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Regulation of PDGF and its receptors in fibrotic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21398330" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195235" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18668566" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18668570" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Is imatinib mesylate a promising drug in systemic sclerosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18668536" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18668587" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Imatinib mesylate treatment of nephrogenic systemic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19180499" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Molecular framework for response to imatinib mesylate in systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18329537" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Novel treatment approaches to fibrosis in scleroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27560196" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17763433" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : B cell infiltration in systemic sclerosis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19180481" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20004954" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19103636" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19447770" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19095294" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22244622" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25573841" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24286447" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Rituximab in severe, treatment-refractory interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24442885" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23118116" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30053212" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38279402" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25433527" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18512816" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31481106" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20506355" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26961294" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37098795" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
